Shunt (electrical)

A Chinese Neurosurgical Journal Study Presents Consensus on the Management of Aneurysmal Subarachnoid Hemorrhage-Related Hydrocephalus

Retrieved on: 
Tuesday, June 13, 2023
Nerve, Drainage, Aneurysm, Shunt (electrical), Quality of life, Brain, Risk, Ambiguity, Cerebrospinal fluid, History, Research, Interventional Neuroradiology, Literature, Subarachnoid hemorrhage, Intracranial pressure, Jugular vein, CSF, Hydrocephalus, Diagnosis, White matter, Capital Medical University, Intraventricular hemorrhage, Medical device

BEIJING, June 13, 2023 /PRNewswire/ -- Aneurysmal subarachnoid hemorrhage-related hydrocephalus (aSAH-H) is a clinical syndrome that leads to excessive accumulation of cerebrospinal fluid (CSF) and ventricle enlargement in the brain. aSAH-H is a complex pathophysiological syndrome, leadingto cognitive impairment and neurological damage. Acute hydrocephalus (less than 3 days of aSAH) can result in a fatal cerebral hernia, whereas chronic hydrocephalus (more than 3 days of aSAH) can adversely affect a patient's quality of life.

Key Points: 
  • Despite the complexity of this condition, there is a lack of diagnostic criteria and treatment protocol for aSAH-H, in China and abroad.
  • Moreover, the lack of consensus among clinicians on the preferred treatment for aSAH-H calls for an urgent need for consistent standards.
  • The study was published in volume 9 of the Chinese Neurosurgical Journal on March 20, 2023.
  • Furthermore, the consensus guideline recommends external ventricular drainage and ensuring the safe removal of the CSF drainage tube in the case of acute hydrocephalus.

QuantalX Receives FDA Breakthrough Designation for Diagnosis of Normal Pressure Hydrocephalus and Prediction of Treatment Response

Retrieved on: 
Tuesday, May 30, 2023
CT, Vascular dementia, Prevalence, Shunt (electrical), DSM-IV codes, Stroke, Quality of life, Alzheimer's disease, Delphi, Cerebrospinal fluid, Dementia, KFAR, MRI, Science, Medtronic, Walking, VPS, Parkinson's disease, Patient, Risk, Physician, Diagnosis, Entrepreneurship, CSF, FDA, Health, NPH, Pharmaceutical industry, Medical imaging, Neuromodulation

KFAR SABA, Israel, May 30, 2023 /PRNewswire/ -- QuantalX, the developer of Delphi-MD, a novel point-of-care neurodiagnostic device, has announced that they have received the prestigious FDA breakthrough designation medical device status for another clinical application, Normal Pressure Hydrocephalus (NPH). The FDA recognized the innovative value of the device in diagnosing NPH patients and predicting the response to the recommended treatment for NPH, ventriculoperitoneal shunting (VPS) surgery.

Key Points: 
  • The FDA grants the Delphi-MD device breakthrough designation technology status for the diagnosis of Normal Pressure Hydrocephalus (NPH) patients and prediction of response to highly effective, ventriculoperitoneal shunting surgery (VPS) treatment.
  • KFAR SABA, Israel, May 30, 2023 /PRNewswire/ -- QuantalX, the developer of Delphi-MD, a novel point-of-care neurodiagnostic device, has announced that they have received the prestigious FDA breakthrough designation medical device status for another clinical application, Normal Pressure Hydrocephalus (NPH).
  • The FDA recognized the innovative value of the device in diagnosing NPH patients and predicting the response to the recommended treatment for NPH, ventriculoperitoneal shunting (VPS) surgery.
  • This marks the second time that the Delphi-MD device has been granted a breakthrough designated medical device by the FDA.